Clinical Trial Update: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial of denosumab (AMG 162) for prevention of postmenopausal osteoporosis completed; results were posted 2010-01-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2010-01-26